PMID- 29264358
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2253-2447 (Print)
IS  - 2253-2447 (Electronic)
IS  - 2253-2447 (Linking)
VI  - 9
DP  - 2017
TI  - Degarelix treatment is compatible with diabetes and antithrombotic therapy in 
      patients with prostate cancer.
PG  - 225-232
LID - 10.2147/RRU.S146180 [doi]
AB  - INTRODUCTION: Therapeutically induced androgen deficiency (AD) is a standard 
      treatment for patients with prostate cancer, but it is often associated with 
      various adverse effects (AEs) that may lead to discontinuation. Some AEs may 
      depend on the patient's health condition, while others may be due to 
      complications of the drug delivery method. Degarelix is a gonadotropin-releasing 
      hormone (GnRH) antagonist widely used for the treatment of androgen-dependent 
      prostate cancer. This study aimed to ascertain the following: 1) the 
      compatibility of degarelix treatment with diabetes and 2) any specific causal 
      associations of degarelix injections with increased blood clotting and 
      antithrombotic therapy requirements. PATIENTS AND METHODS: The medical records of 
      162 patients with prostate cancer who had undergone degarelix treatment were 
      retrospectively examined. The association of a medical history of diabetes and 
      anticoagulant co-treatment with degarelix treatment discontinuation was analyzed 
      statistically. RESULTS: Rapid and significant decreases in prostate-specific 
      antigen (PSA) levels during the course of degarelix treatment were detected for 
      patients with prostate cancer regardless of clinical state. During the 27 months 
      of treatment, 68 subjects (48%) ceased degarelix treatment, owing to several 
      reasons, mainly financial issues. Among these subjects, 19 had diabetes, while 35 
      were treated with antithrombotics. Extensive statistical analysis indicated that 
      there were no causal associations between degarelix treatment discontinuation and 
      preexisting diabetes or antithrombotic therapy. CONCLUSION: Our study suggests 
      that preexisting diabetes and antithrombotic therapy were not significant factors 
      for the discontinuation of degarelix treatment in patients with prostate cancer.
FAU - Tokiwa, Suguru
AU  - Tokiwa S
AD  - Department of Urology, Jyoban Hospital, Tokiwa Foundation, Iwaki, Fukushima, 
      Japan.
FAU - Shimmura, Hiroaki
AU  - Shimmura H
AD  - Department of Urology, Jyoban Hospital, Tokiwa Foundation, Iwaki, Fukushima, 
      Japan.
FAU - Nomura, Shuhei
AU  - Nomura S
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial 
      College London, London, UK.
AD  - Department of Global Health Policy, Graduate School of Medicine, The University 
      of Tokyo, Tokyo.
AD  - Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki.
FAU - Watanabe, Ryota
AU  - Watanabe R
AD  - Department of Urology, Jyoban Hospital, Tokiwa Foundation, Iwaki, Fukushima, 
      Japan.
FAU - Kurita, Minoru
AU  - Kurita M
AD  - Department of Urology, Jyoban Hospital, Tokiwa Foundation, Iwaki, Fukushima, 
      Japan.
FAU - Yoshida, Naoto
AU  - Yoshida N
AD  - Department of Urology, Jyoban Hospital, Tokiwa Foundation, Iwaki, Fukushima, 
      Japan.
FAU - Yamashita, Kaori
AU  - Yamashita K
AD  - Department of Urology, Jyoban Hospital, Tokiwa Foundation, Iwaki, Fukushima, 
      Japan.
FAU - Nishikawa, Yoshitaka
AU  - Nishikawa Y
AD  - Department of Health Informatics, School of Public Health, Kyoto University, 
      Kyoto, Japan.
FAU - Kouzmenko, Alexander
AU  - Kouzmenko A
AD  - Department of Life Sciences, Alfaisal University, Riyadh, Kingdom of Saudi 
      Arabia.
FAU - Kato, Shigeaki
AU  - Kato S
AD  - Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki.
LA  - eng
PT  - Journal Article
DEP - 20171206
PL  - England
TA  - Res Rep Urol
JT  - Research and reports in urology
JID - 101576971
PMC - PMC5724412
OTO - NOTNLM
OT  - GnRH antagonists
OT  - antithrombotic treatment
OT  - degarelix
OT  - diabetes
OT  - discontinuation
OT  - prostate cancer
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/12/22 06:00
MHDA- 2017/12/22 06:01
PMCR- 2017/12/06
CRDT- 2017/12/22 06:00
PHST- 2017/12/22 06:00 [entrez]
PHST- 2017/12/22 06:00 [pubmed]
PHST- 2017/12/22 06:01 [medline]
PHST- 2017/12/06 00:00 [pmc-release]
AID - rru-9-225 [pii]
AID - 10.2147/RRU.S146180 [doi]
PST - epublish
SO  - Res Rep Urol. 2017 Dec 6;9:225-232. doi: 10.2147/RRU.S146180. eCollection 2017.